Implantica strengthens market expansion as Italy’s leading Careggi University Hospital in Florence introduces RefluxStop®

Implantica announced that Italy’s Careggi University Hospital in Florence has performed its first RefluxStop® procedure, marking adoption of the CE‑marked anti‑reflux implant at a major European center; the surgery was led by Dr. Paolo Prosperi and is part of Implantica’s strategy to scale the technology across high‑volume centers of excellence. RefluxStop®, which restores the lower esophageal sphincter without encircling the esophagus and therefore aims to avoid common side effects of traditional anti‑reflux surgery, has been used in more than 1,400 patients in Europe and is presented as a potential paradigm shift in GERD treatment. The move strengthens Implantica’s commercial momentum in a large addressable market—GERD affects an estimated 1 billion people globally (up to ~20% in Italy)—and supports further rollout efforts; Implantica is listed on Nasdaq First North Premier (ticker: IMP A SDB).

Analysis

Implantica announced that Careggi University Hospital in Florence performed its first RefluxStop® procedure (press release dated December 10, 2025), led by Dr. Paolo Prosperi with Dr. Alessio Giordano assisting; the device is CE‑marked and Implantica reports more than 1,400 RefluxStop® patients treated across Europe. The company emphasizes a large addressable market — GERD affects an estimated 1 billion people worldwide with up to ~20% prevalence in Italy — and positions Careggi’s adoption as a strategic step in scaling the therapy across high‑volume centers of excellence.

RefluxStop® is presented as clinically differentiated from conventional anti‑reflux surgery because it does not encircle the esophagus and therefore aims to avoid common side effects such as dysphagia, pain on swallowing and inability to belch or vomit; Implantica states the device reconstructs three components of the anti‑reflux barrier and may represent a paradigm shift in treatment. Careggi’s endorsement by performing the first procedure at a major university hospital supports growing clinical confidence but remains an early commercial proof point.

Near‑term implications are clinical validation and incremental commercial momentum in Europe, which could de‑risk rollout if reimbursement and larger center adoption follow; material uncertainties remain because the announcement cites company‑reported outcomes rather than new peer‑reviewed data, and no revenue, pricing or reimbursement details were disclosed. Investors should therefore treat this as a positive operational milestone that requires follow‑on evidence on clinical publications, adoption velocity and payer coverage to move the investment thesis materially.

Key Decisions for Investors

• Monitor verification milestones: look for peer‑reviewed clinical data, additional major hospital adoptions and explicit reimbursement or pricing announcements before increasing exposure to Implantica
• Treat Careggi adoption as an incremental positive but maintain a cautious position size until adoption scales beyond the 1,400 reported patients and commercial revenue or coverage metrics emerge
• If already invested, set catalysts (published RCTs, multi‑center registries, formal reimbursement decisions in key EU markets) as triggers to add, and consider hedging event risk around slower-than-expected rollout or regulatory setbacks